Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of natalizumab re-initiation after dosing suspension in multiple sclerosis
2005-004061-41Phase 3Terminated
- Sponsor
- Biogen
- Start
- Oct 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of natalizumab in multiple sclerosis (MS), sponsored by Biogen. Primary endpoint: Safety and tolerability of natalizumab re-initiation. Started Oct 2005; status: terminated.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2005-004061-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004061-41.